Two other LSD1 inhibitors, SP-2577 (Seclidemstat) and CC-90011 (Purodemstat), are under evaluation in patients with hematological malignancies, but their evaluation in AML patients is, at the moment, very limited. This evidence concerns the gene KDM1A and acute myeloid leukemia.